Vonoprazan/amoxicillin/clarithromycin

Vonoprazan/amoxicillin/clarithromycin, sold under the brand name Vonosap among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection.^[1][4] It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker; amoxicillin, a beta-lactam antibiotic; and clarithromycin, a macrolide antibiotic.^[1][4]

Vonoprazan/amoxicillin/clarithromycin

Combination of
Vonoprazan	Potassium-competitive acid blocker
Amoxicillin	Beta-lactam antibiotic
Clarithromycin	Macrolide antibiotic
Clinical data
Trade names	Vonosap, Voquezna Triple Pak
License data	US DailyMed: Voquezna
ATC code	A02BD14 (WHO)
Legal status
Legal status	US: ℞-only[1][2] Rx-only[3]
Identifiers
KEGG	D10775

It was approved for medical use in Japan in 2016,^[3] and in the United States in May 2022.^[1][2][5][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[7][8]